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Objective: Approaches to monitoring of sepsis have traditionally relied upon the pro-inflammatory com-
ponent of the sepsis response. This study evaluated the diagnostic and prognostic potential of the ratio
of neutrophilic CD64 (nCD64) and monocytic HLA-DR (mHLA-DR) median fluorescence index in monitoring
of neonatal sepsis.
Methods: Blood from 100 neonates suspected of sepsis and 29 healthy controls was collected on clin-
ical suspicion of sepsis, and the expression of nCD64, mHLA-DR was evaluated by Flow Cytometry;
thereby, a derived parameter “Sepsis index,” SI5 nCD64/mHLA-DR 3 100 was estimated.
Results: At day 1, sensitivity and specificity to detect sepsis using nCD64 was 73.01% and 89.18%,
respectively, while for SI it was 73.01% and 72.22%, respectively. On Kaplan-Meier analysis, neonates
with SI> cut-off showed a higher 30 day-mortality than those with low SI (P5 0.096). On multivariate
analysis, the factor associated with mortality in our cohort was Apgar score 3, while SI showed a trend
toward significance.
Conclusions: At day1, nCD64 is useful for the diagnosis of neonatal sepsis whereas mHLA-DR is bene-
ficial for monitoring patients at a later time point. The SI is a marker of moderate diagnostic sensitivity
and supplements the current arsenal of laboratory investigations to detect neonatal sepsis. As a marker
of prognosis, a high SI shows a trend towards greater mortality. VC 2015 Clinical Cytometry Society
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INTRODUCTION
Sepsis constitutes one of the leading causes of mortal-
ity and morbidity in the neonatal period worldwide
(1–3). When left untreated, neonatal sepsis can poten-
tially turn fulminant, making early diagnosis and inter-
vention an essential component of the therapeutic strat-
egy (4). Blood culture remains the gold standard for
diagnosis of neonatal sepsis, but reports generally
require 48–72 h in most settings. In addition, it has a
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low sensitivity in detecting sepsis (5), thus limiting its
application as a decision making tool for initiation of
antimicrobial therapy. Accordingly, considerable atten-
tion has been focused on development of criteria for
detection of infections in neonates to guide commence-
ment of empirical therapy (4). On the other hand, since
deterioration of health can be sudden and rapid, early
prognostication of neonates is of crucial importance (6).
Flow cytometry based monitoring with biomarkers for
sepsis has provided tools to assist the clinical decision
making in sepsis (7) with CD64, the Fc-gamma recep-
tor1 on neutrophils, emerging as a potential marker in
the diagnosis of sepsis, its increased expression repre-
senting a pro-inflammatory response to infection (7–10).
It has been shown to be effective in monitoring sepsis
in critically ill adults with infection (11) and in serial
monitoring of neonates (12). In adults, a raised CD64 on
neutrophils has been associated with poor prognosis
(11), while in neonates there is lack of such evidence
(13). On the other hand, decreased expression of HLA-
DR molecules on circulating monocytes has been associ-
ated with an anti-inflammatory immune response,
referred to as “immunoparalysis” in sepsis (14,15).
While the diagnostic significance of HLA-DR is limited
(16), a decrease in HLA-DR on monocytes has been asso-
ciated with deaths in adults (17) and newborn infections
(18,19).
As progression and eventual mortality in sepsis is a
trade-off between pro and anti-inflammatory responses,
we hypothesized an ideal parameter to guide the man-
agement of cases should include monitoring of pro- and
anti-inflammatory markers of sepsis such as CD64 and
HLA-DR, respectively, i.e., ratio of nCD64 and mHLA-DR.
The current study evaluated this parameter by flow
cytometry to determine its diagnostic efficacy in sepsis
in a neonatal intensive care unit (NICU) and its applic-
ability in predicting prognosis in terms of mortality.
MATERIALS AND METHODS
Study Population
This prospective observational study was conducted
from March 2012 to March 2013 in the NICU of Insti-
tute of Post Graduate Medical Education & Research
(IPGME&R), Kolkata. Neonates (<28 days) of either sex
having a suspicion of sepsis were recruited irrespective
of their birth weight, day of life and gestational age. The
clinical criteria included modified body temperature,
core temperature >38.5 C or <36 C and/or tempera-
ture instability, cardiovascular instability (bradycardia,
mean heart rate <10th percentile for the age in absence
of external stimulus or congenital heart or otherwise
unexplained persistent depression over 30 minutes or
tachycardia, mean heart rate >2 SD above normal for
age in the absence of external stimulus, drugs and pain
or otherwise unexplained persistent elevation over a 30
minutes to 4 h and/or rhythm instability), reduced uri-
nary output (<1 mL/kg/h), hypotension (mean arterial
pressure less than the 5th percentile for age), mottled
skin, impaired peripheral perfusion, skin and subcutane-
ous lesions (petechial rash, sclerema), respiratory insta-
bility (apnea episodes or tachypnea episodes, mean
respiratory rate (RR) over 2 SD above normal for age or
increased oxygen requirements or requirement for venti-
lation support), gastrointestinal (feeding intolerance,
poor sucking, abdominal distention) along with non-
specific irritability, lethargy and hypotonia. When two or
more of these criteria were positive, as per European
Medical Agency (EMA) guidelines (20), blood was col-
lected for culture and antimicrobials subsequently
administered; cases receiving G-CSF therapy were
excluded. Healthy controls comprised neonates having
no suspicion of sepsis and were being routinely
screened for congenital hemoglobinopathies. The study
was approved by the Institutional Ethics Committee of
IPGME&R, Kolkata; informed consents were obtained
from the legally acceptable representatives.
Microbial Culture
On clinical suspicion of sepsis, blood culture was per-
formed (BACTEC 9050, Becton Dickinson, MD). Wher-
ever clinically indicated, cultures of cerebrospinal fluid
(CSF), urine, endotracheal tube, central catheter tips
and pus were performed; they were considered positive
when bacteria isolated were not skin commensals. For
study classification, the false positive cases were consid-
ered as culture negative; if the culture report stated it
was a skin commensal, yet the neonate appeared clini-
cally septic, a repeat culture was performed.
Time Points for Sampling of Blood
Blood samples for flow cytometric (FCM) analysis
were obtained on initial suspicion of sepsis, wherein
blood was collected for culture and laboratory screen-
ing. Blood was also analysed for C-reactive protein
(CRP), total leukocyte count (TLC), determination of
immature/total (I/T) neutrophil ratio, platelet count
(PC), base excess and random glucose levels. In addi-
tion, examination of CSF for protein, glucose, total and
differential count, serum electrolytes (Na1, K1, Ca21)
etc., was performed, when clinically indicated. Other
investigations including chest and abdominal X-rays
whenever indicated; in controls, TLC, PC, and CRP were
measured.
Case Classification
Cases were broadly classified into two categories,
namely “infected” and “non-infected.” The infected cases
were further sub-grouped into (i) “culture positive
sepsis”: if culture was positive from any biological source,
or (ii) culture negative “clinical sepsis”: if 2 or more labo-
ratory parameters were positive, namely TLC> 20,000/mL
or <4,000/mL; I/T ratio>0.2; PC< 1,00,000/mL; glucose
values <45 mg/dL or >180 mg/dL; base excess<-10 mEq/
L and CRP>15 mg/L (20). Cases that failed to meet the cri-
teria for the ‘infected’ group were considered as non-
infected. Clinicians remained blinded to all FCM results
and the latter did not influence the study classification.
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FCM Analysis
Blood for FCM analysis was collected in EDTA vials
and processed within 4 h of collection, except in 2 sam-
ples where it was delayed to 6 h. Between collection
and processing, the vials were stored at 2–8 C. During
processing, 50 mL blood was added to Tube 1: gating
markers, anti-CD15-FITC and anti-CD14-FITC and Tube
2; anti-HLA-DR-PerCPCy5.5, anti-CD64-APC and gating
markers. The antibody clones were anti-CD15 antibody
(FITC): W6D3; anti-CD14 antibody (FITC): MoP9; anti-
CD64 antibody (APC):10.1; anti-HLA-DR antibody
(PerCP-Cy5.5): L234. All FCM related reagents were
from BD Biosciences (San Jose, CA).
Whole blood was incubated with the antibodies for
15 minutes at room temperature (RT) after which lysis
buffer (FACSLyseTM) was added; after further incubation
for 15 minutes at RT, 100 mL of distilled water was
added; the instrument was calibrated using FACS-
CompTM beads. The “lyse-no-wash” setting was modified
to keep a threshold on the FITC channel and atleast
20,000 events were collected. The gating strategy used
to distinguish neutrophils from monocytes relied upon
differential side scatter along with CD15 or CD14
expression, respectively. Neutrophils were identified as
events with SSChiCD15hi and monocytes were identified
as SSCmidCD14hi. Expression of the marker of interest
within gated neutrophils and monocytes was measured
in terms of median fluorescence intensity (MFI) and ana-
lyzed using CellQuestPro software (BD Biosciences, San
Jose, CA) (Fig. 1).
FIG. 1. Immunophenotyping and gating strategy. 20,000 events were collected; Neutrophils and monocytes were gated based on FSC/FITC bivari-
ate dot plot using CD15 and CD14 expression, respectively. Expression was noted in terms of MFI. Neutrophilic CD64 was designated as nCD64
and monocytic mHLA-DR as mHLA-DR. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Derivation of “Sepsis Index”
Neutrophilic CD64 was designated as nCD64 and
monocytic HLA-DR as mHLA-DR. To combine changes in
the expression of pro-inflammatory (nCD64) and anti-
inflammatory (mHLA-DR) markers, we evaluated a com-
posite parameter by arithmetic division of MFI values of
nCD64 and their respective mHLA-DR and multiplying
the ratio by 100, and this was termed as “Sepsis Index”
Sepsis Index ¼ nCD64 3 100
mHLA2DR
Laboratory Investigations
CRP was measured by nephelometry (BN ProspecVR
System, Siemens, Germany), detection threshold being
3.19 mg/L. For analyses as a numerical variable, meas-
urements reported as <3.19 mg/L were all assigned a
constant value of 3.18 mg/L. TLC and PC was measured
in Sysmex 3-part Differential Automated Hematology
Analyzers (Sysmex America Inc., Mundelein, IL), base
excess was measured in Cobas b 221 Blood Gas system,
Roche, Germany and the I/T ratio was determined by a
pathologist.
Statistical Analysis
Statistical analyses were performed on GraphPad
Prism Version 5.0 (GraphPad Software, San Diego, CA,
2007) and SPSS Version 16.0.1 (SPSS, Chicago, IL, 2007).
Results are presented as median and interquartile range.
For FCM data, in cases where an up-regulation in study
parameter was noted, the 90th percentile of controls
(excluding outliers) was selected as the diagnostic cut-
off; values above this were considered as “positive.” On
the other hand, for downregulated parameters, 10th per-
centile of the controls was taken as the cut-off, and val-
ues below this were considered “positive.” Based on
these cut-offs, sensitivity and specificity to detect sepsis
was calculated.
All data sets were tested for normality as also paired
and unpaired data compared using appropriate statistical
tests. To identify the prognostic relevance, survival anal-
ysis based on 30-day mortality was performed. To assess
the predictability of 30-day mortality by various clinical
and laboratory parameters after adjusting for confound-
ers, a binary logistic regression modeling was per-
formed. P <0.05 was considered statistically significant
while P <0.2 was considered to show a trend towards
significance (21).
RESULTS
Study Population
A total of 106 cases and 29 healthy controls were
recruited; incomplete data was available in 6 cases;
accordingly, 100 cases were analyzed. The cases were
classified into “infected” (n5 63) or “non-infected”
(n5 37). Based on positivity of laboratory parameters,
the infected cases were subclassified into culture posi-
tive sepsis (n5 21) and clinical sepsis (n5 42). Demo-
graphic characteristics, treatment variables and labora-
tory parameters are shown in Table 1 and culture yields
in Supporting Information 1.
FCM Parameters and Sepsis Index
In the infected group, expression of nCD64 was sig-
nificantly upregulated while mHLA-DR was significantly
downregulated as compared to the non-infected group
and healthy controls (Table 2). The Sepsis Index (nCD64
x 100/mHLA-DR) was significantly higher in infected
than non-infected neonates and healthy controls (Table
2). The median SI in the infected group was 3.01 fold
higher than the non-infected group, vis-a-vis a 2.24 fold
increase in nCD64 in the infected group as compared to
the non-infected group.
Sensitivity and Specificity of Study Parameters to Detect
Sepsis
To measure the sensitivity and specificity of SI for
detection of infected cases, the 90th percentile of MFI
values of healthy controls was considered as the cut-off,
and was 92.66. Accordingly, the sensitivity and specific-
ity of SI at Day 1 was 73.01% and 72.22%, respectively
(Table 3). Similarly, the cut-off for nCD64 was calculated
to be 126.10. The sensitivity and specificity of nCD64 at
day 1 was 73.01% and 89.18%, respectively. The cut-off
for mHLA-DR was 69.26 (10th percentile of MFI values
of healthy controls); the sensitivity for detection of sep-
sis at day 1 was 25.39% while specificity was 83.33%.
To enhance the sensitivity of detection of sepsis, a
combination of parameters were analyzed. Since the sen-
sitivity of mHLA-DR was too low, it was excluded from
assessing in combination with other parameters. A combi-
nation of nCD64 and/or SI at day 1 increased the sensitiv-
ity to 84.12%, an improvement of 11.11% over either
alone, indicating only partial overlap between the subsets
of sepsis cases detected by individual markers. If positiv-
ity of SI and/or positivity of 2 laboratory criteria was
compared with SI alone, the sensitivity at day 1 increased
by 14.29%. Similarly, nCD64 when combined with labora-
tory criteria at day 1, the sensitivity increased by 11.11%
(Table 3). A combination of nCD64, SI and positivity of
2 laboratory criteria increased the sensitivity to 90.47%
at day 1. Effect of antimicrobial therapy on the FCM
parameters is included in Supporting Information 2.
Prognosticating Survival
At day 1, up-regulation of SI, downregulation of
mHLA-DR and a low Apgar score showed a trend
towards significance when 30 day non-survivors and sur-
vivors amongst infected cases were compared (Table 4).
However, it is important to note that the median mHLA-
DR amongst non-survivors was greater than the cut-off
as decided by the 10th percentile of healthy controls.
This essentially means that at least 50% of the non-
surviving sepsis cases would have mHLA-DR levels in
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the range of healthy controls; importantly, in case of SI,
such an overlap with healthy controls was not observed.
To explore whether a high SI conferred a higher risk
of 30-day mortality in sepsis amongst those with infec-
tion (n5 63, deaths5 13), they were sub-grouped as
SI 92.66 or SI> 92.66; on survival analysis, a high SI
(>92.66) showed a trend toward higher mortality
(P5 0.096), while the majority of deaths (12/13,
92.30%) showed an upregulated SI. The association with
mortality was stronger in case of SI, than mHLA-DR<
69.26 (P5 0.190), as only 38.4% (5/13) showed a low
mHLA-DR (<69.26). SI also showed a stronger associa-
tion with mortality than nCD64 >126.10 (P5 0.705)
and CRP >15 mg/L (P5 0.153).
For identifying the predictive value of various demo-
graphic and laboratory parameters after adjusting for
confounders of mortality in neonatal sepsis, binary
regression modeling was performed on the infected
cases (n5 63). Accordingly, parameters that showed a
trend toward differences between survivors and non-
survivors in Table 4 with a P< 0.2 were selected for the
predictive model after converting into binary variables.
Accordingly, Apgar score (> or 3) (22), IT ratio (>
or 0.2), PC (<1,00,000/mL or 1,00,000/mL), mHLA-
DR (<69.26 MFI or 69.26 MFI) and SI (>92.66 or
92.66) consisted of independent variables. On per-
forming a logistic regression, an Apgar score 3 [odds
ratio 11.61 (1.06–127.20), P5 0.045] showed the great-
est predictive ability while SI >92.66 [odds ratio 4.46
(0.46–42.69), P5 0.194] showed a trend towards signifi-
cance (Table 5). The Nagelkerke R square for the model
was 0.305, with an overall correct prediction of 84.10%.
DISCUSSION
Early diagnosis of neonatal sepsis is difficult owing to
the non-specific nature of its signs (4), while crucial
therapeutic decisions like administration of antimicro-
bials require strategically timed quantifiable laboratory
data. Therefore, the need for an “all-purpose” monitor-
ing marker is paramount to guide clinicians to diagnose
and prognosticate mortality early in the disease course;
accordingly, this study examined the diagnostic and
prognostic role of innate immunity markers in neonatal
sepsis, individually and in combination.
Expression of nCD64 is effective in diagnosing neona-
tal sepsis (23), but its diagnostic efficacy varied from
26–97% (sensitivity) and 71–100% (specificity), possibly
due to population heterogeneity, assay methodologies
and case classification criteria (23). We considered
median of the fluorescence intensity as the reporting
parameter, as fluorescence intensity is typically a
skewed data. The ROC curve analysis was not used to
define the cut-off for nCD64, to allow for comparison of
data between neonatal centers. Instead, sensitivity and
specificity of parameters and their combinations were
calculated based on the 90th percentile of healthy con-
trols for parameters that are upregulated and 10th per-
centile in case of down regulated parameters. However,
had a ROC curve analysis been done, results would have
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been similar as the diagnostic cut-off by both approaches
was similar (Supporting Information Content 3). The diag-
nostic sensitivity and specificity of nCD64 at day 1 was in
concordance with a metanalysis (24) and importantly, the
sensitivity and specificity of nCD64 in neonatal sepsis
was calculated as defined by EMA guidelines (20),
thereby ensuring a standard case definition. Downregula-
tion of mHLA-DR in neonatal sepsis (19,25) was corrobo-
rated in our study, but mHLA-DR alone showed a poor
diagnostic utility (Table 2).
As the progression of sepsis is a balance between pro
and anti-inflammatory responses, phenomena that are
not temporally distinct (26,27), capturing the effect of
both mechanisms may be an effective approach to moni-
tor sepsis. Pro-inflammatory markers like CRP or nCD64
typically have a protracted rise following pathogenic
challenge (28) whereas the anti-inflammatory response
like downregulation of mHLA-DR is relatively rapid and
more representative of physiological changes (25).
Accordingly, a composite parameter, “Sepsis Index (SI)”
was derived which when considered alone showed mod-
erate sensitivity and specificity (Table 3); however, in
combination with nCD64, the diagnostic sensitivity
increased substantially (Table 3), reiterating the impor-
tance of using both parameters. At day 1, the best sensi-
tivity of 90.47% was obtained when positivity of nCD64,
SI and 2 EMA criteria were considered (Table 3). The
data strongly indicated that when all three parameters
are negative at day 1, withdrawal of antimicrobials may
be considered. Since the current median number of
days of administration of antimicrobials in non-infected
cases in our setting was four, this information could
obviate 3 days of antimicrobial administration, thus
translating into decreased health costs and reduced
emergence of antimicrobial resistance.
Various FCM methods can predict prognosis in sepsis
episodes (13,17,29) with up-regulation of nCD64 being
associated with increased mortality in adults (30,31)
while non-survivors showed a down-regulation (32);
however, in neonatal sepsis, nCD64 showed no prognos-
tic significance (13). Our study corroborated the same,
as in terms of a 30-day survival, nCD64 levels at day 1
showed no prognostic significance. However, mHLA-DR
was downregulated in adults and critically ill neonates
(14,25) and in adults, was indicative of mortality only at
day 3–4 (17,33). Although mHLA-DR was downregulated
in non-survivors of sepsis at the very onset, non-
survivors were significantly younger than survivors, but
no adjustment for multivariate analysis had been done
(18), whereas variation of mHLA-DR with postnatal age
is documented (25). On the other hand, Ng et al. dem-
onstrated no significant difference in mHLA-DR expres-
sion between infected and non-infected or control
groups (16). In this study, a trend analysis of mHLA-DR
indicated that mHLA-DR was significantly downregulated
in non-survivors only at a later stage, i.e., days 4–6 (Sup-
porting Information content 4 and Fig. S1).
On survival analysis at day 1, neonates with higher SI
showed a trend towards higher mortality (Fig. 2) and in
multivariate analysis, Apgar score 3 emerged as an
important predictor of mortality, concurring with previ-
ous reports (34); SI showed a trend towards significance,
Table 2
Flow Cytometric Parameters and SI on Day 1
Parameter Infected n Non-infected n Healthy Controls n P values
nCD64 (MFI) 186.00 (117.60–237.10) 63 82.79 (71.46–107.00) 37 79.86 (69.16–111.20) 29 <0.001a
mHLA-DR (MFI) 98.22 (66.12–128.60) 63 121.30 (93.28–237.10) 36 154.00 (109.20–213.90) 29 <0.001a
SI 173.1 (90.58–333.8) 63 57.40 (30.45–127.80) 36 53.52 (41.27–76.36) 29 <0.001a
Data is represented as median (inter-quartile range) or as number of patients (n).
aSignificant differences between Infected vs. Non-infected and Infected vs. healthy controls in post-hoc analysis.
Table 3
Sensitivity and Specificity of Markers for Neonatal Sepsis
Parameter with respective cut-offs n Sensitivity (%) Specificity (%)
SI> 92.66 on day 1 99 73.01 72.22
nCD64 >126.10 on day 1 100 73.01 89.18
mHLA-DR  69.26 on day 1 99 25.39 83.33
nCD64>126.10 and/or SI >92.66 on day 1 99 84.12 69.44
SI >92.66 and/or 2 laboratory criteria
positive, on day 1
99 87.3 72.22
nCD64 >126.10 and/or 2 laboratory
criteria positive, on day 1
100 84.12 89.18
nCD64>126.10 and/or SI >92.66 and/or
2 laboratory criteria positive on day 1
99 90.47 69.40
To measure the sensitivity and specificity of nCD64 for detection of infected cases, 90th percentile of the MFI values of 27 neo-
nates (excluding two outliers) was chosen as the cut-off and was calculated to be 126.10. The cut-off for SI was similarly calcu-
lated based on the 90th percentile of the SI values from 28 neonates (excluding one outlier) and found to be 92.66. For mHLA-
DR, the cut-off of 69.26 was obtained by calculating 10th percentile of the controls (excluding one outlier).
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being much higher than the predictive value of mHLA-
DR. As clinical deterioration can be sudden and rapid,
the clinician has limited time to intervene, and therefore,
a delayed prognosticator will have limited relevance
(35). As a high SI showed a trend toward the early pre-
diction of mortality, it deserves exploration in future
studies.
An important limitation is the use of CRP as a refer-
ence standard and as part of the EMA criteria and the
index tests, leaving the chance of bias. However, if such
an assessment was performed as in clinical practice, a
combination of markers can best detect sepsis. Measure-
ment of Procalcitonin, an emerging marker of sepsis
would have been an ideal comparator, but its exorbitant
cost precluded the same. Differentiation between mono-
cytes and neutrophils was done using CD14 and CD15,
respectively, and although CD14 is mainly expressed on
monocytes, the abundant presence of myeloid precur-
sors in a patient with sepsis could cause an overlap
with monocytes. However, CD14 expression on neutro-
phils or myeloid precursors, if present, would be signifi-
cantly dimmer. It is important however that monocytes
and neutrophils are better discriminated, and future
studies should keep this in mind. Furthermore, as a sin-
gle lot of reagents and instrument was used, future stud-
ies should aim to standardize the assay between instru-
ments, reagent lots and institutions. In addition, the
CD64 clone used was 10.1, which is known to be infe-
rior relative to other clones like 22 and 32.2, although
with functionally comparable performances (36); ideally,
validation of these clones is necessary. Further, use of a
lyse-no-wash staining protocol necessitated triggering
the instrument on its FITC channel to exclude RBC
debris which resulted in exclusion of lymphocytes from
the acquisition gate. However, as lymphocytes can
potentially serve as an internal negative control for
CD64, exploring a stain-lyse-wash protocol with thresh-
old on the forward scatter channel could be considered.
In addition, comparison with validated assays for nCD64
(Trillium Diagnostics) and combination reagents in a sin-
gle tube should be considered.
In conclusion, our data provides evidence that as an
independent parameter, nCD64 is more useful in diagno-
sis of neonatal sepsis, whereas the SI adds to the overall
diagnostic sensitivity at patient admission. In addition,
the downregulation of mHLA-DR might help in identifica-
tion of delayed immunosuppression in neonatal sepsis,
and is potentially indicative of a poorer prognosis. At an
early stage, a high SI level trends toward greater mortality,
Table 4
Differences in Day 1 Levels Between 30-Day Survivors and Non-survivors
Parameter Survivors (n550) Non-survivors (n513) P values
Male/Female 31/19 9/4 0.753
Day of Life (days) 4.50 (2.00 – 11.00) 3.00 (1.50–11.00) 0.467
Gestational age (weeks) 36.00 (32.00 – 39.00) 36.00 (29.00–38.00) 0.369
Birth weight (gm) 2,010 (1,471 – 2,370) 2,250 (1,063–2,790) 0.772
Apgar score at 5 minutes 8.00 (6.00 – 8.00) 6.00 (3.00–8.00) 0.063
CRP(mg/L) 7.14 (3.18 – 21.15) 15.20 (4.41–52.75) 0.218
TLC(103/mL) 10.40 (7.92–16.80) 12.90 (8.20–23.80) 0.312
I/T Ratio 0.14 (0.07–0.21) 0.13 (0.04–0.17) 0.168
PC (103/mL) 170.50 (87.75–254.00) 95.00 (70.00–189.00) 0.179
Base Excess (mEq/L) 23.65 (26.92 to 20.95) 26.200 (29.5 to 21.55) 0.570
Glucose (mg/dL) 81.50 (65.75–103.10) 82.00 (54.50–109.00) 0.513
nCD64 (MFI) 168.50 (116.5–229.8) 211.00 (127.90–274.00) 0.269
mHLA-DR (MFI) 103.20 (70.18–138.60) 69.78 (49.37–104.10) 0.058
SI 164.00 (86.83–312.00) 302.30 (103.3–506.2) 0.066
Data is represented as median (inter-quartile range) or as number of patients.
Table 5
Risk Factors and Their Adjusted Odds Ratio for 30 Day-
Mortality As Analyzed by Binary Logistic Regression
Independent variable
Adjusted odds
ratio (95% CI) P values
Apgar score 3 11.61 (1.06–127.20) 0.045
IT ratio >0.2 0.25 (0.02–2.30) 0.222
PC <1,00,000/mL 1.52 (0.36–6.27) 0.563
mHLA-DR (MFI) <69.26 0.94 (0.19–46.78) 0.948
SI>126.10 4.46 (0.46–42.69) 0.194
FIG. 2. Kaplan–Meier survival plot stratified for SI below or above
the cut-off (92.66 MFI).
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but definitive evidence of its advantage over information
obtained from nCD64 and mHLA-DR remains to be
substantiated.
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